Table 1 

Efficacy (% resolution of incontinence) and discontinuation data included into the economic model 

% Resolution of incontinence (<1 episode/24 hrs) 
W2 
W8 
W12 
W12W8 
W12~W8 



Placebo 
20,99% 
34,66% 
27,84% 
80,33% 
14,16% 

Fesoterodine 4 mg 
30,41% 
50,00% 
43,67% 
87,34% 
21,05% 

Fesoterodine 8 mg 
40,59%^{a} 
55,38%^{a} 
50,21% 
90,65% 
24,20% 

Tolterodine 
29,23% 
49,47% 
38,18% 
77,17% 
13,04% 

Solifenacin 5 mg^{c} 
31,49% 
51,99% 
41,76% 
80,33%^{d} 
21,24% 

Solifenacin 10 mg^{e} 
32,11%^{a} 
53,01%^{a} 
42,58% 
80,33%^{d} 
21,66%^{b} 



Other data 
% Nocturia (> = 2 episodes/night) % of patients with nocturia at baseline without nocturia at W12 
Constipation 



Placebo 
54,34% 
1,99% 

Fesoterodine 4 mg 
55,56% 
4,15% 

Fesoterodine 8 mg 
55,90% 
6,01% 

Tolterodine 
57,69% 
2,76% 

Solifenacin 5 mg 
54,34%^{i} 
3,53%^{j} 

Solifenacin 10 mg 
88,72%^{j} 
7,72%^{j} 



Discontinuation 
W2 
W8 
W12 
W24^{f} 
W52^{f} 



Placebo 
100% 
92,84% 
90,64% 
79,32% 
59,27% 

Fesoterodine 4 mg 
100% 
92,67%^{g} 
equal to placebo data ^{h} 

Fesoterodine 8 mg 
 
 
equal to placebo data ^{h} 

Tolterodine 
100% 
95,76% 
equal to placebo data ^{h} 

Solifenacin 5 mg 
100% 
94,06% 
equal to placebo data ^{h} 

Solifenacin 10 mg 
 
 
equal to placebo data ^{h} 



The symbol "" denotes conditional response rates; the response at week 12 given response at week 8. The symbol "~" denotes nonresponse; noresponse at week 12 given noresponse at week 8 Source: Fesoterodine phase III trials, except when a different source is described [17,18]. a  values not used in the decision tree; only used to calculate conditional response rates b  conditional response rates estimated by applying the W8 low dose: high dose response ratio to the W12~W2(~W8) nontitrating response rate c  equal to 1,5 times the placebo rates [29] d  conditional response equal to placebo rate e  equal to 1,5294 times the placebo rates [29] f  W24 and W52 values were extrapolated from clinical trial data using an exponential decay curve fitted to W2, W8, and W12 discontinuation values g  discontinuation rate of fesoterodine 4 mg at W8 in the trial data was greater than that of placebo at W12, therefore this value was set equal to the W12 rate. h  discontinuation rates at week 12 were found to be not statistically significant for any treatment [30], therefore the values are equal to placebo discontinuation i  relative rates from published literature [42]; solifenacin 5 mg not found to be significantly different than placebo; solifenacin 10 mg 63.28% higher than placebo j  relative rates from published literature [29]; solifenacin 5 mg 1,778 times placebo; solifenacin 10 mg 3,889 times higher than placebo 

ArlandisGuzman et al. BMC Urology 2011 11:9 doi:10.1186/14712490119 